The evolving role of PET/CT in breast cancer

Nuclear Medicine Communications

Volumn 31, Issue 4, 2010, Pages 271-273

  Groheux, David ^a,b   Giacchetti, Sylvie ^a   Rubello, Domenico ^c   Al Nahhas, Adil ^d   Moretti, Jean Luc ^a,b   Espié, Marc ^a   Hindié, Elif ^a,b  

^a Saint Louis Hospital   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c ROVIGO GENERAL HOSPITAL   (Italy)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORIDE SODIUM; FLUORODEOXYGLUCOSE F 18; TRACER;

ADVANCED CANCER; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; HUMAN; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; REVIEW; ADJUVANT THERAPY; BREAST TUMOR; EDITORIAL; LYMPH NODE; METASTASIS; METHODOLOGY; PATHOLOGY; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; TREATMENT OUTCOME;

BREAST NEOPLASMS; HUMANS; LYMPH NODES; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77954472400     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283354cb4     Document Type: Review

References (24)

1. Townsend D. Dual-modality imaging: combining anatomy and function. J Nucl Med 2008;49:938-955.
2. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;1:3495-3502.
3. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 2007;14:260-268.
4. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007;73:1151-1157.
5. 18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009;96:166-170.
6. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor positive/progesterone receptor-positive/HER2 negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008;112:995-1000.
7. 18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746-4751.
8. 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002;75:135-146.
9. Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, et al. Effect of (18) F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71:695-704.
10. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253-1258.
11. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105-112.
12. Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, Langsteger W. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2009 [Epub ahead of print]
13. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27:535-541.
14. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008;247:189-196.
15. 18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006;12:6437-6443.
16. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267-274.
17. Groheux D, Moretti JL, Giacchetti S, Hindié E, Teyton P, Cuvier C, et al. PET/CT in breast cancer: an update. Bull Cancer 2009;96:1053-1070.
18. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277-285.
19. Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 2009;36:1543-1550.
20. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005;65:5907-5916.
21. Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005;46:658-666.
22. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-1347.
23. 18F-fluoroestradiol. J Nucl Med 2008;49:367-374.
24. 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008;49:68-78.